Director/PDMR Shareholding
Updated : 17:24
Grant of options
Oxford, UK - 23 August 2019: Circassia Pharmaceuticals plc ("Circassia" or "the Company"; LSE: CIR), a specialty biopharmaceutical company focused on respiratory disease, announces that it has granted options ("Options") today over 1,884,602 new ordinary shares of 0.08 pence each in the Company ("Ordinary Shares") (representing 0.50% per cent. of the Company's issued share capital) to certain directors of the Company under the 2019 Performance Share Plan.
The Options have been granted at a price of 0.08 pence per Ordinary Share, will vest on the third anniversary of the date of grant and are exercisable until the tenth anniversary of the date of grant. Vesting is subject to share price and sales performance conditions.
Name | Position | Options Issued | Awards and Options Held Post Issue |
Steven Harris | Chief Executive Officer | 803,200 | 1,961,771 |
Julien Cotta | Chief Financial Officer | 518,728 | 1,329,194 |
Rod Hafner | Senior Vice President of R&D | 562,674 | 1,250,681 |
Contacts
Circassia Steve Harris, Chief Executive Officer Julien Cotta, Chief Financial Officer Rob Budge, Corporate Communications
| Tel: +44 (0)1865 405560
|
Peel Hunt (Nominated Adviser and Joint Broker) James Steel / Dr Christopher Golden
| Tel: +44 (0) 20 7418 8900
|
Numis Securities (Joint Broker) James Black / Freddie Barnfield
| Tel: +44 (0) 20 7260 1000
|
FTI Consulting Simon Conway / Ciara Martin | Tel: +44 (0) 20 3727 1000
|
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||||||
a. | Name | 1. Steven Harris 2. Julien Cotta 3. Rod Hafner | ||||||||
2. | Reason for the notification | |||||||||
a. | Position/status | 1. Chief Executive Officer 2. Chief Financial Officer 3. Senior Vice President of R&D | ||||||||
b. | Initial notification /Amendment
| Initial notification | ||||||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
a. | Name | Circassia Pharmaceuticals plc | ||||||||
b. | LEI | 2138006YAT138TOGA556 | ||||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
a. | Description of the Financial instrument, type of instrument Identification code | Options over Ordinary shares of 0.08p each.
GB00B1VKB244 | ||||||||
b. | Nature of the transaction | Award of share options granted under the 2019 Performance Share Plan over Ordinary Shares in Circassia
| ||||||||
c. | Price(s) and volume(s) | Numbers 1 to 3 in the left hand column correspond to the relevant PDMR as detailed in boxes 1a and 2a above.
| ||||||||
d. | Aggregated information · Aggregated volume · Price
|
n/a
| ||||||||
e. | Date of the transaction | 2019-08-23 | ||||||||
f. | Place of the transaction | Outside a trading venue
|
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.